KC
NBIX icon

Kepos Capital’s Neurocrine Biosciences NBIX Stock Holding History

Kepos Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-34,545
Closed -$2.92M – 377
2019
Q2 		$2.92M Sell
34,545
-19,794
-36% -$1.63M 0.3% 55
2019
Q1 		$4.79M Hold
54,339
– – 0.36% 91
2018
Q4 		$3.88M Hold
54,339
– – 0.3% 100
2018
Q3 		$6.68M Buy
+54,339
New +$6.17M 0.34% 51

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kepos Capital's NBIX Position: Q3 2019 in Review

Kepos Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 34,545 shares — an estimated $2.92M sold.

Kepos Capital first reported a position in NBIX in Q3 2018 and held it in 4 quarters. The position peaked at $6.68M in Q3 2018. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Kepos Capital reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Kepos Capital sold 34,545 Neurocrine Biosciences shares in Q3 2019, an estimated $2.92M.
  • Kepos Capital first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 4 quarters.
  • Kepos Capital's Neurocrine Biosciences position peaked at $6.68M in Q3 2018.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Kepos Capital's 13F filing for Q3 2019, filed 13 Nov 2019.